Short-term prognostic factors of rituximab combined with glucocorticoids in the treatment of pemphigus: A multicenter retrospective study

Published: 24 August 2026| Version 2 | DOI: 10.17632/5kyn787nnr.2
Contributors:
Zhili Wu, Jiefeng Jiang, Shuomin Chen, Yiqian Peng, Xueting Yang, Yiu Nam, Cong Zhang, Feng Guo, Gang Hu, Guiying Zhang, Jinbo Chen, Ruzeng Xue

Description

Supplementary Table 1: This table compares the baseline clinical and laboratory characteristics between pemphigus patients who achieved complete remission on minimal therapy (CR mini) and those who did not. Supplementary Table 2: This table details the baseline characteristic differences between pemphigus patients who experienced short-term relapse after rituximab treatment and those who remained in remission. Supplementary Table 3: This table presents the univariate logistic regression analysis of potential baseline factors influencing the achievement of CR mini in rituximab-treated pemphigus patients. Supplementary Table 4: This table provides the univariate logistic regression results evaluating potential baseline risk factors for short-term relapse in pemphigus patients following rituximab therapy.

Files

Institutions

Categories

Biologic Agent, Pemphigus

Licence